Related Experiment Video

Updated: Jan 5, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.2K

How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?

Sevda Önder1, Murat Ozturk2

  • 1Department of Dermatology, Ordu University Medical Faculty, Ordu, Turkey.

Cutaneous and Ocular Toxicology
|October 24, 2019
PubMed

Insights

Omalizumab treatment significantly reduced neutrophil counts and ratios in chronic spontaneous urticaria (CSU) patients. This suggests a potential anti-inflammatory effect, warranting further investigation into treatment response correlation.

Area of Science:

  • Immunology
  • Dermatology
  • Hematology

Background:

  • Chronic spontaneous urticaria (CSU) is a complex condition often requiring advanced therapies.
  • Understanding the immunoinflammatory markers associated with CSU is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate the impact of omalizumab on specific immunoinflammatory cell ratios in patients with CSU.
  • To assess changes in hematological parameters following 12 weeks of omalizumab therapy.

Main Methods:

  • Retrospective analysis of 74 CSU patients treated with omalizumab (2016-2019).
  • Comparison of hematological parameters, including neutrophil/lymphocyte ratio (NLR) and neutrophil/monocyte ratio (NMR), before and after 12 weeks of treatment.
  • Investigation of angioedema status and total IgE levels in relation to treatment outcomes.

Main Results:

  • Omalizumab treatment led to a statistically significant reduction in neutrophil count.
  • Significant decreases were observed in the neutrophil/lymphocyte ratio (NLR) and neutrophil/monocyte ratio (NMR) after 12 weeks.
  • No significant changes were noted in other examined parameters, such as lymphocyte/monocyte ratio (LMR) and platelet/lymphocyte ratio (PLR).

Conclusions:

  • Omalizumab therapy demonstrably reduces specific neutrophil-related inflammatory markers in CSU patients.
  • The observed decrease in NLR and NMR suggests a potential anti-inflammatory mechanism of omalizumab.
  • Further research is necessary to correlate these hematological changes with treatment efficacy and explore their role in predicting response to omalizumab.

Keywords:
Omalizumabanti-inflammatory effectchronic spontaneous urticariahematologıcal parameterslymphocyte/monocyte rationeutrophil/lymphocyte rationeutrophil/monocyte ratioplatelet/lymphocyte ratio

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

409
Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.1K

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
986
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
424
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K